1. Name of the medicinal product:

Nostamine Eye & Nasal Sterile Solution

2. Qualitative and quantitative composition:

Each 1 ml contains:

For excipients see section 6.1

3. Pharmaceutical form:

A clear colorless solution preserved in a tight, light resistance plastic dropper bottles.

4. Clinical particulars:

4.1 Therapeutic indications:

Nose: Common cold, symptomatic treatment of rhinitis, sinusitis and allergic rhinitis.

Eye: Spring catarrh and allergic manifestation of the eye.

4.2 Posology and Method of Administration

Nose: 2 drops 4 times daily in each nostril.

Eye: 1-2 drops 3 - 6 hours.

4.3 Contraindications:

Narrow angle glaucoma.

4.4 Special warnings and precautions for use:

None

4.5 Interaction with other medicinal products:

None

4.6 pregnancy and lactation:

None.

4.7 Effects on ability to drive and use machines:

None.

4.8 Undesirable effects:

Uncommon; mild transient stinging with frequent application may occur.

4.9 Overdose:

No action other than medical observation should be necessary.

5. Pharmacological properties:

5.1 Pharmacodynamic properties:

Nostamine contains naphazoline HCL which has a potent quick vasoconstrictor effect and chlorpheniramine maleate which has a marked antihistaminic effect.

Nostamine produces a rapid and prolonged decongestion of the nasal mucosa and congunctiva.

5.2 Pharmacokinetic properties:

None.

5.3 Preclinical safety data

There are no pre-clinical data.

6. Pharmaceutical particulars:

6.1 List of excipients:

Sodium citrate dihydrate, boric acid, benzalkonium chloride, disodium edetate, purified water.

6.2 Incompatibilities:

None known

6.3 Shelf life:

3 years.

6.4 Special precautions for storage:

Store at temp. 15° - 30° C.

It should be used within 1 month after opening.

6.5 Nature and contents of container:

Bottles of 10 ml and 15 ml.

6.6 Special precautions for disposal and other handling:

Do not use if the drops change color or become cloudy.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder:

EIPICO

8. Date of revision of the text

August 2024